Analyst Yanan Zhu from Wells Fargo maintained a Hold rating on Fate Therapeutics (FATE – Research Report) and keeping the price target at $4.00.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Yanan Zhu has given his Hold rating due to a combination of factors surrounding Fate Therapeutics’ recent clinical data. The early results for their off-the-shelf CAR-T therapy, FT819, in treating SLE/LN patients are promising, particularly given its innovative approach and reduced conditioning requirements. However, the small sample size and limited follow-up period mean that more data is needed to fully understand the therapy’s consistency and long-term effectiveness.
While the initial efficacy indicators, such as SLEDAI-2K score reductions and proteinuria improvements, are encouraging, the variability in patient responses and the need for more comprehensive data to assess the therapy’s durability contribute to the cautious outlook. This uncertainty, combined with the inherent risks of clinical trials and the competitive landscape, supports the decision to maintain a Hold rating until further information becomes available.
Zhu covers the Healthcare sector, focusing on stocks such as uniQure, Regulus, and Ionis Pharmaceuticals. According to TipRanks, Zhu has an average return of -5.3% and a 30.74% success rate on recommended stocks.
In another report released yesterday, Bank of America Securities also maintained a Hold rating on the stock with a $2.20 price target.